These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 20159523)

  • 1. Novel targets for pancreatic cancer therapy.
    Philip PA
    Surg Oncol Clin N Am; 2010 Apr; 19(2):419-29. PubMed ID: 20159523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic cancer: from molecular signature to target therapy.
    Longo R; Cacciamani F; Naso G; Gasparini G
    Crit Rev Oncol Hematol; 2008 Dec; 68(3):197-211. PubMed ID: 18436450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatic cancer: progress in cancer therapy.
    Pierantoni C; Pagliacci A; Scartozzi M; Berardi R; Bianconi M; Cascinu S
    Crit Rev Oncol Hematol; 2008 Jul; 67(1):27-38. PubMed ID: 18356073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant therapy and biliary decompression lower biliary and pancreatic juice vascular endothelial growth factor levels in patients with periampullary adenocarcinoma.
    Berger AC; Watson JC; Ross EA; Zalatoris A; Hoffman JP
    Am Surg; 2004 Feb; 70(2):169-73; discussion 173-4. PubMed ID: 15011922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant therapy for resectable pancreatic adenocarcinoma: review of the current treatment approaches and future directions.
    Antoniou G; Kountourakis P; Papadimitriou K; Vassiliou V; Papamichael D
    Cancer Treat Rev; 2014 Feb; 40(1):78-85. PubMed ID: 23810287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pancreatic cancer: from molecular pathogenesis to targeted therapy.
    Strimpakos A; Saif MW; Syrigos KN
    Cancer Metastasis Rev; 2008 Sep; 27(3):495-522. PubMed ID: 18427734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapies for non-small cell lung cancer.
    Dempke WC; Suto T; Reck M
    Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting signal transduction pathways in colorectal cancer--more than skin deep.
    Cohen SJ; Cohen RB; Meropol NJ
    J Clin Oncol; 2005 Aug; 23(23):5374-85. PubMed ID: 15998904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future.
    Cohenuram M; Saif MW
    JOP; 2007 Jan; 8(1):4-15. PubMed ID: 17228128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer.
    Hochster HS; Haller DG; de Gramont A; Berlin JD; Philip PA; Moore MJ; Ajani JA
    Cancer; 2006 Aug; 107(4):676-85. PubMed ID: 16847885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.
    Maione P; Gridelli C; Troiani T; Ciardiello F
    Oncologist; 2006 Mar; 11(3):274-84. PubMed ID: 16549812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New frontiers in pancreatic cancer research.
    Khan GN; di Magliano MP; Simeone DM
    Surg Oncol Clin N Am; 2010 Apr; 19(2):431-51. PubMed ID: 20159524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translation of recent advances and discoveries in molecular biology and immunology in the diagnosis and treatment of pancreatic cancer.
    Albo D; Farrow B; Berger DH
    Surg Oncol Clin N Am; 2008 Apr; 17(2):357-76, ix. PubMed ID: 18375357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced stage pancreatic cancer: novel therapeutic options.
    Saif MW
    Expert Rev Clin Pharmacol; 2014 Jul; 7(4):487-98. PubMed ID: 24939470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel therapies for pancreatic cancer.
    Wolff RA
    Cancer J; 2001; 7(4):349-58. PubMed ID: 11561610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of nuclear factor kappaB in pancreatic cancer and the clinical applications of targeted therapy.
    Holcomb B; Yip-Schneider M; Schmidt CM
    Pancreas; 2008 Apr; 36(3):225-35. PubMed ID: 18362834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer.
    El Maalouf G; Le Tourneau C; Batty GN; Faivre S; Raymond E
    Cancer Treat Rev; 2009 Apr; 35(2):167-74. PubMed ID: 19027240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translational research. New findings and potential future applications in pancreatic adenocarcinoma.
    Strimpakos AS; Syrigos KN; Saif MW
    JOP; 2012 Mar; 13(2):177-9. PubMed ID: 22406595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas.
    Hidalgo M; Von Hoff DD
    Clin Cancer Res; 2012 Aug; 18(16):4249-56. PubMed ID: 22896691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying pancreatic cancer patients for targeted treatment: the challenges and limitations of the current selection process and vision for the future.
    Showalter SL; Charles S; Belin J; Cozzitorto J; Einstein P; Richards NG; Sauter PK; Kennedy EP; Witkiewicz A; Brody JR; Yeo CJ
    Expert Opin Drug Deliv; 2010 Mar; 7(3):273-84. PubMed ID: 20201734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.